No abstract

SF-36 data are not available at the national level; hence, the authors recommend that their study results may serve as the normative reference for SF-36 in Mexico. Researchers using the SF-36 could compare their results with our reference, adjusted by gender and age in population-based studies. Considering that the study regions have contrasting social and economic characteristics, the data from the more developed state, Sonora, may be used as the normative standard. Data from Oaxaca would be used as the reference for less-developed states. The English version of this paper is available at: http://www.insp.mx/salud/index.html.

OBJETIVO: Evaluar el estado de salud de los ancianos mexicanos a través de la autopercepción y analizar los factores sociales, de salud y organizacionales asociados. MÉTODOS: Estudio de datos secundarios de la Encuesta Nacional de Salud 2000 en México. Se realizó análisis de regresión logística múltiple. La variable dependiente fue el estado de salud medido a través de la autopercepción de salud. Las variables independientes seleccionadas fueron: características sociodemográficas, hábitos de riesgo, accidentes, diagnóstico de enfermedades y mediciones clínicas. RESULTADOS: Se analizó a 7,322 adultos de 60 años y mayores, que representan al total de la población (7%) en ese grupo de edad en México. De estos, 19.8% reportó estado de salud como malo o muy malo. Los factores asociados a mala salud fueron edad, sexo femenino, no tener seguro social, ser divorciado, dedicarse al hogar, estar incapacitado, no tener trabajo, consumo de tabaco, problema de salud, accidentes y diagnóstico de enfermedades crónicas. CONCLUSIONES: El análisis de factores asociados permitió determinar elementos que influyen en mal estado de salud de ancianos. Los hallazgos podrían considerarse en la formulación de acciones y programas de atención para esa población en México.

BackgroundWe know little about how procurement of a high-risk medical device (HRMD) affects clinical practice and outcomes. In health systems in high-income countries, and specifically those that maintain a national arthroplasty registry, procurement decisions are frequently guided by long-term clinical results, with the goal of ensuring at least standard quality of HRMDs. But in countries like Mexico, decision-making is often dominated by lowest acquisition price. We set out to study the impact of procurement for orthopaedic HRMDs on clinical procedures and outcomes.MethodsWe based our qualitative study on 59 in-depth interviews with stakeholders from Mexico, Switzerland, Germany, and UK: orthopaedic specialists, government officials, other experts, and social security system managers or administrators. We took a healthcare delivery approach to capturing and comparing factors that affected the regulations of HRMDs and procurement processes, and to understanding connections between procurement and clinical practice.ResultsOur findings demonstrate for procurement processes that the three European countries compared to Mexico don’t have similar concerns with regards to their procurement processes. Deficiencies of procurement regulations and practices identified from representatives in Mexico were almost absent in European countries. We identified three areas of deficiency: 1) HRMD regulations based on insufficiently robust clinical evidence (mainly noted by European countries); 2) Follow-up on Health Technology Assessments is inadequate (noted by Mexico) and methodology not always good enough (noted by European countries); and, 3) Lowest-acquisition price often guides procurement decisions and thus may not align with needs of clinical procedures (noted by Mexico and some European countries).ConclusionsProcurement processes for orthopaedic HRMDs may have an impact on clinical procedures and outcomes. A favourable approach is one where orthopaedic specialists are parties to the procurement process, and post-market surveillance data informs decision-making. Actors in the procurement process can improve their impact on clinical procedures and outcomes by developing specific strategies that better align the needs of both, procurement and clinical procedures.

The current guideline is the result of constructive collaboration among a multidisciplinary research team to better ascertain the true economic burden of dengue across countries of the region.